Saturday, March 30, 2013 7:51:05 PM
2013 WILL BE A BREAKOUT YEAR FOR CBMX. THE CEO PREDICTS POSITIVE CASH FLOW "RELATIVELY QUICKLY" BASED ON THE FOLLOWING TRENDS:
- SALES FOR CBMX HIGH MARGIN PRENATAL TESTS ROSE 172% IN 2012.
-15% GROWTH RATE IN 2012 SHOULD ACCELERATE in 2013 as oncology stabilizes and PRENATAL REVENUE CONTINUES TO RAMP.
- CBMX has a current market cap of $4 million, which is a fraction of other companies in the Molecular diagnostics space. ROSG trades at a $40 MM market cap. If CBMX traded at same valuation it would be $30.
- CBMX has streamlined the organization and slashed costs to the bone.
- Tightly held 1.2 Million float.
- CBMX traded at $17 in 2012, and 2013 results will be far better.
In short, CBMX has all the ingredients to go much higher in a very short time frame.
HIGHLIGHTS:
- 1.2 MM share float.
- $4 MM market cap.
- 170% growth rate in most profitable segment, prenatal tests.
- Growth will accelerate in 2013 and cash flow positive reached "relatively quickly" per CEO guidance.
- Traded at $17+ in 2012.
-Trading at 90% discount to peers.
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM